Skip to main content

Advertisement

SpringerLink
Log in

PET–CT with (68 Ga)Gallium-Labeled PSMA Ligand for the Diagnosis of Prostate Cancer: Clinical Applications and Protocols

  • PET/CT Imaging (R Morgado, Section Editor)
  • Published:
Current Radiology Reports Aims and scope Submit manuscript

Abstract

The detection of lesions in the context of biochemical recurrence of prostate cancer is a major challenge for all imaging modalities. Recently, the prostate-specific membrane antigen (PSMA) is recognized as a novel target for the PET–CT (positron emission tomography–computed tomography) imaging of prostate cancer with the tracer 68Ga-PSMA (68Gallium-labelled PSMA), mainly in the detection of relapses and metastasis. PSMA PET–CT imaging shows high tracer uptake at the sites of primary tumor and lymph node, and bone metastasis in direct correlation with aggressiveness and Gleason scores. PSMA PET–CT seems to be a highly accurate imaging tool for restaging of prostate cancer patients with biochemical recurrence, and it proved to be clearly superior in detecting prostate cancer lesions at low PSA levels when compared to other methods.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.

    Article  PubMed  Google Scholar 

  2. Kabasakal L, AbuQbeitah M, Aygün A, Yeyin N, Ocak M, Demirci E, Toklu T. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(13):1976–83.

    Article  CAS  PubMed  Google Scholar 

  3. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528–39.

    Article  CAS  PubMed  Google Scholar 

  4. Chang SS, O’Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res. 1999;5:2674–81.

    CAS  PubMed  Google Scholar 

  5. Samplaski MK, Heston W, Elson P, Magi-Galtuzzi C, Hansel DE. Folate hydrolase (prostate-specific membrane [corrected] antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature. Mod Pathol. 2011;24:1521–9.

    Article  CAS  PubMed  Google Scholar 

  6. Wang W, Tavora F, Sharma R, Eisenberger M, Netto GJ. PSMA expression in Schwannoma: a potential clinical mimicker of metastatic prostate carcinoma. Urol Oncol. 2009;27:525–8.

    Article  CAS  PubMed  Google Scholar 

  7. • Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM. PET imaging with a [68 Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013; 40(4):486–95. The importance of this study was to establish a normal pattern of concentration of PSMA in different segments and to evaluate its applicability for tumour imaging by calculating the ratio between radiotracer uptake in tumour lesions and background.

  8. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81–5.

    CAS  PubMed  Google Scholar 

  9. • Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A, et al. [(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42(2):210–4. In this article the authors demonstrate the importance of knowledge uptake in coeliac ganglia that can mimic lymph node metastasis.

  10. Perner S, Hofer MD, Kim R, Shah RB, Li H, Moller P, Hautmann RE, Gschwend JE, Kuefer R, Rubin MA. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38:696–701.

    Article  CAS  PubMed  Google Scholar 

  11. Sterzing F, Kratochwil C, Fiedler H, Katayama S, Habl G, Kopka K, Afshar-Oromieh A, Debus J, Haberkorn U, Giesel FL. 68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2016;43(1):34–41.

    Article  CAS  PubMed  Google Scholar 

  12. • Afshar-Oromieh A, et al. The diagnostic value of PET/CT imaging with the 68 Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. (2015);42(2):197–209. 68 Ga-PSMA-ligand PET/CT can detect prostate cancer in a high percentage of patients with suspected neoplasm (82.8%). Any uptake of 68 Ga-PSMA-HBED-CC in lesions above local background is highly specific for prostate cancer and must therefore be regarded as prostate cancer unless otherwise proven. This article provides an analysis of the diagnostic value of 68 Ga-PSMA-ligand PET–CT in a large cohort and the influence of several possibly interacting variables.

  13. Eiber M, et al. Evaluation of hybrid 68 Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):668–74.

    Article  PubMed  Google Scholar 

  14. Ceci F, et al. 68 Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42(8):1284–94.

    Article  PubMed  Google Scholar 

  15. Dimmen M, Vlatkovic L, Hole KH, Nesland JM, Brennhovd B, Axcrona K. Transperineal prostate biopsy detects significant cancer in patients with elevated prostate-specific antigen (PSA) levels and previous negative transrectal biopsies. BJU Int. 2012;110(2 Pt 2):E69–75.

    Article  PubMed  Google Scholar 

  16. Gayet M, Van der Aa A, Beerlage HP, Schrier BP, Mulders PF, Wijkstra H. The value of magnetic resonance imaging and ultrasonography (MRI/US)-fusion biopsy platforms in prostate cancer detection: a systematic review. BJU Int. 2016;117(3):392–400.

    Article  PubMed  Google Scholar 

  17. Schimmoller L, et al. MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy. Eur Radiol. 2014;24:2582–9.

    Article  PubMed  Google Scholar 

  18. Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, Beer AJ, Wester HJ, Gschwend J, Schwaiger M, Maurer T. Simultaneous 68 Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol. 2016. doi:10.1016/j.eururo.2015.12.053.

    Google Scholar 

  19. Jadvar H. Molecular imaging of prostate cancer: PET radiotracers. AJR Am J Roentgenol. 2012;199(2):278–91.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Maurer T, et al. Diagnostic efficacy of 68gallium-PSMA- PET compared to conventional imaging in lymph node staging of of 130 consecutive patients with intermediate to high-risk prostate cancer. J Urol. 2015. doi:10.1016/j.juro.2015.12.025.

    PubMed  Google Scholar 

  21. Pfister D, et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol. 2014;65:1034–43.

    Article  PubMed  Google Scholar 

  22. Beresford MJ, Gillatt D, Benson RJ, Ajithkumar T. A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. Clin Oncol (R Coll Radiol). 2010;22:46–55.

    Article  CAS  Google Scholar 

  23. Krause BJ, et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:18–23.

    Article  CAS  PubMed  Google Scholar 

  24. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J, Haberkorn U. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20.

    Article  CAS  PubMed  Google Scholar 

  25. Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I, Wester HJ. Lutetium-177 PSMA radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016. doi:10.2967/jnumed.115.168443.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Hospital Beneficência Portuguesa de São Paulo, Rua Maestro Cardim, 769 - Bela Vista, São Paulo, SP, CEP: 01323-001, Brazil

    Letícia Rigo, Daian de Bona Pessoa, Anna Carolina Borges & Pricila Gama da Cunha

  2. Department of Radiology, Hospital Beneficência Portuguesa de São Paulo, Rua Maestro Cardim, 769 - Bela Vista, São Paulo, SP, CEP: 01323-001, Brazil

    Felipe Roth Vargas

Authors
  1. Letícia Rigo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daian de Bona Pessoa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Carolina Borges
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pricila Gama da Cunha
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Felipe Roth Vargas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Letícia Rigo.

Ethics declarations

Conflict of Interest

Letícia Rigo, Daian de Bona Pessoa, Anna Carolina Borges, Pricila Gama da Cunha, and Felipe Roth Vargas each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on PET–CT Imaging.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rigo, L., de Bona Pessoa, D., Borges, A.C. et al. PET–CT with (68 Ga)Gallium-Labeled PSMA Ligand for the Diagnosis of Prostate Cancer: Clinical Applications and Protocols. Curr Radiol Rep 4, 65 (2016). https://doi.org/10.1007/s40134-016-0189-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s40134-016-0189-1

Keywords

Search

Navigation